logo-loader
Vitality Biopharma Inc

Vitality Biopharma CEO says cannabinoids have potential for neurological/inflammatory conditions

Vitality Biopharma (OTCQB:VBIO) CEO Robert Brooke tells Proactive Investors about the company's development of cannabinoid prodrug pharmaceuticals and how cannabinoids can be used for the treatment of serious neurological and inflammatory disorders.

Brooke says the cannabinoid prodrugs (known as cannabosides) can, upon ingestion, enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. This could be used by people with conditions such as Crohn's, IBS and colitis.

Brooke says cannabinoids also have the potential to be used as an alternative to opiate abuse.

Quick facts: Vitality Biopharma Inc

Price: $0.20

Market: OTCQB
Market Cap: $10.46 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Musgrave Minerals signs $18 million earn-in JV with...

Musgrave Minerals Ltd (ASX:MGV) managing director Robert Waugh updates Proactive on the signing of an $18 million earn-in joint venture agreement with Evolution Mining centred on the Lake Area of the Cue Project in W.A.  Evolution can earn 75% in the area by sole funding $18 million in...

27 minutes ago

2 min read